ArticleFrontiers in immunology2025
Unveiling the hidden cardiovascular risk of sipuleucel-T: a pharmacovigilance analysis using the FDA Adverse Event Reporting System, 2010-2025.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sipuleucel-T, the first therapeutic cancer vaccine approved by the U.S. Food and Drug Administration (FDA), represents a crucial treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). However, the characteristics of cardiovascular adverse events (CVAEs) associated with sipuleucel-T remain poorly understood. Methods: This retrospective, pharmacovigilance analysis used case safety reports from the FDA Adverse Event Reporting System (FAERS) spanning April 2010 to March 2025. Reporting odds ratio (ROR) and information component (IC) were applied to identify and evaluate potential CVAEs associated with sipuleucel-T. Kaplan-Meier method and Weibull distribution were used to analyze reported time-to-onset patterns of sipuleucel-T-related CVAEs. Multivariate logistic regression was employed to explore risk factors for CVAEs following sipuleucel-T treatment. Results: Among 4,797 sipuleucel-T-related reports, 743 (15.49%) documented CVAEs, of which 427 (57.5%) were classified as serious. Positive CVAE signals associated with sipuleucel-T included hypertension, venous thromboembolic events, arterial thromboembolic events, cardiac failure, cardiac arrhythmias, and myocardial infarction. The median time to onset of sipuleucel-T-related CVAEs was 14 days, with 80.11% occurring within 1 month. Moreover, the median time to onset of fatal CVAEs was significantly later than that of non-fatal CVAEs (22 days Conclusions: This study characterizes the clinical spectrum, time-to-onset patterns, and risk factors of sipuleucel-T-associated CVAEs, providing essential pharmacovigilance data for managing patients with mCRPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.